| [1] |
Houben RM, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med, 2016, 13(10): e1002152. doi:10.1371/journal.pmed.1002152.
|
| [2] |
World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
|
| [3] |
Cui X, Gao L, Cao B. Management of latent tuberculosis infection in China: Exploring solutions suitable for high-burden countries. Int J Infect Dis, 2020, 92S: S37-S40. doi:10.1016/j.ijid.2020.02.034.
pmid: 32114201
|
| [4] |
中国医学科学院病原生物学研究所, 中国疾病预防控制中心, 中国科学院地理科学与资源研究所. 全国结核分枝杆菌潜伏感染率估算专家共识. 中国防痨杂志, 2022, 44(1): 4-8. doi:10.19982/j.issn.1000-6621.20210662.
|
| [5] |
Zenner D, Beer N, Harris RJ, et al. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med, 2017, 167(4): 248-255. doi:10.7326/M17-0609.
pmid: 28761946
|
| [6] |
赵雁林, 陈明亭. 中国结核病防治工作技术指南. 北京: 人民卫生出版社, 2021.
|
| [7] |
徐彩红, 赵雁林. 中国结核病预防性治疗指南. 北京: 人民卫生出版社, 2023.
|
| [8] |
Ruan QL, Yang QL, Ma CL, et al. Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB). Emerg Microbes Infect, 2025, 14(1): 2502010. doi:10.1080/22221751.2025.2502010.
|
| [9] |
Winters N, Belknap R, Benedetti A, et al. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med, 2023, 11(9): 782-790. doi:10.1016/S2213-2600(23)00096-6.
pmid: 36966788
|
| [10] |
World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
|
| [11] |
Liu X, Thompson J, Dong H, et al. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. Lancet Glob Health, 2023, 11(5): e693-e703. doi:10.1016/S2214-109X(23)00068-2.
|
| [12] |
Lam CK, McGinnis Pilote K, Haque A, et al. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study. J Med Internet Res, 2018, 20(11): e287. doi:10.2196/jmir.9825.
|
| [13] |
中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8): 761-768. doi:10.3969/j.issn.1000-6621.2020.08.001.
|
| [14] |
秦楠, 宁晨曦, 张祖荣, 等. 结核病患者手机应用程序督导服药的应用及其影响因素. 中国卫生资源, 2023, 26(4): 358-362, 369. doi:10.13688/j.cnki.chr.2023.230133.
|
| [15] |
西尔扎提·阿布力克木, 阿不都艾则孜·吉力力, 地力夏提·萨里. 2008—2017年新疆伊犁州直属地区肺结核病疫情监测分析. 疾病预防控制通报, 2019, 34(1): 61-63. doi:10.13215/j.cnki.jbyfkztb.1805003.
|
| [16] |
马平, 贵有军, 阿卜杜艾力·阿提拜克, 等. 2013—2021年新疆伊宁县肺结核流行特征分析. 疾病预防控制通报, 2024, 39(2): 44-46. doi:10.13215/j.cnki.jbyfkztb.2309008.
|
| [17] |
Sterling TR, Moro RN, Borisov AS, et al. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis, 2015, 61(4): 527-535. doi:10.1093/cid/civ323.
pmid: 25904367
|
| [18] |
Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011, 365(23): 2155-2166. doi:10.1056/NEJMoa1104875.
|
| [19] |
Sterling TR, Scott NA, Miro JM, et al. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS, 2016, 30(10): 1607-1615. doi:10.1097/QAD.0000000000001098.
pmid: 27243774
|
| [20] |
Wolfe A, Jadhav P, May A, et al. Latent TB treatment regimens in 2023: Wetmore TB clinic in New Orleans. J Clin Tuberc Other Mycobact Dis, 2024, 35: 100443. doi:10.1016/j.jctube.2024.100443.
|
| [21] |
Li W, Wu S, Su M, et al. Barriers and facilitators to the implementation of electronic monitors to improve adherence and health outcomes in patients with tuberculosis: a systematic review. Lancet Infect Dis, 2024, 25(3): e153-e164. doi:10.1016/S1473-3099(24)00587-5.
|